United Therapeutics Corporation (NASDAQ:UTHR) - Equities research analysts at Leerink Swann reduced their FY2019 earnings per share (EPS) estimates for United Therapeutics Corporation in a report issued on Monday. Leerink Swann analyst J. Schwartz now forecasts that the biotechnology company will post earnings of $7.06 per share for the year, down from their prior forecast of $7.49.
UTHR has been the subject of several other reports. ValuEngine lowered United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, June 2nd. BidaskClub raised United Therapeutics Corporation from a “sell” rating to a “hold” rating in a report on Friday, June 16th. Credit Suisse Group reissued an “underperform” rating and issued a $120.00 price objective on shares of United Therapeutics Corporation in a report on Monday, April 3rd. J P Morgan Chase & Co set a $125.00 price objective on United Therapeutics Corporation and gave the company a “hold” rating in a report on Tuesday, April 11th. Finally, Wedbush reissued an “outperform” rating and issued a $229.00 price objective on shares of United Therapeutics Corporation in a report on Tuesday, April 4th. Five investment analysts have rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $134.50.
Shares of United Therapeutics Corporation (UTHR) traded up 0.40% during mid-day trading on Thursday, hitting $131.77. The company had a trading volume of 204,517 shares. United Therapeutics Corporation has a 52-week low of $110.72 and a 52-week high of $169.89. The stock’s 50-day moving average is $130.12 and its 200-day moving average is $137.41. The stock has a market cap of $5.94 billion, a price-to-earnings ratio of 9.25 and a beta of 1.52.
United Therapeutics Corporation (NASDAQ:UTHR) last announced its earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.12 by $0.77. The firm had revenue of $370.50 million during the quarter, compared to analysts’ expectations of $399.59 million. United Therapeutics Corporation had a return on equity of 34.74% and a net margin of 41.04%. The business’s revenue was up .4% on a year-over-year basis. During the same period in the prior year, the firm earned $3.02 EPS.
Several institutional investors have recently modified their holdings of UTHR. BlackRock Inc. increased its position in shares of United Therapeutics Corporation by 4,222.8% in the first quarter. BlackRock Inc. now owns 4,741,985 shares of the biotechnology company’s stock valued at $641,969,000 after buying an additional 4,632,287 shares in the last quarter. AQR Capital Management LLC increased its position in shares of United Therapeutics Corporation by 27.8% in the first quarter. AQR Capital Management LLC now owns 1,736,357 shares of the biotechnology company’s stock valued at $235,068,000 after buying an additional 377,395 shares in the last quarter. Vanguard Group Inc. increased its position in shares of United Therapeutics Corporation by 7.3% in the first quarter. Vanguard Group Inc. now owns 3,785,099 shares of the biotechnology company’s stock valued at $512,427,000 after buying an additional 256,514 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in shares of United Therapeutics Corporation by 142.6% in the first quarter. BNP Paribas Arbitrage SA now owns 365,204 shares of the biotechnology company’s stock valued at $49,441,000 after buying an additional 214,687 shares in the last quarter. Finally, Old Mutual Global Investors UK Ltd. increased its position in shares of United Therapeutics Corporation by 32.7% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 820,823 shares of the biotechnology company’s stock valued at $111,123,000 after buying an additional 202,479 shares in the last quarter.
In other news, CEO Martine A. Rothblatt sold 1,265 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $119.40, for a total transaction of $151,041.00. Following the completion of the transaction, the chief executive officer now directly owns 1,405 shares in the company, valued at $167,757. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Christopher Causey sold 590 shares of the business’s stock in a transaction that occurred on Thursday, July 6th. The stock was sold at an average price of $132.61, for a total value of $78,239.90. Following the transaction, the director now owns 3,875 shares of the company’s stock, valued at $513,863.75. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,547 shares of company stock valued at $2,886,839. 7.80% of the stock is currently owned by insiders.
United Therapeutics Corporation declared that its Board of Directors has initiated a stock buyback program on Thursday, April 27th that allows the company to buyback $250.00 million in shares. This buyback authorization allows the biotechnology company to repurchase up to 4.6% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its stock is undervalued.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
